Quality of anticoagulation with warfarin in rural Chhattisgarh, India

被引:6
|
作者
Chebrolu, Puja [1 ]
Patil, Sushil [4 ]
Laux, Timothy S. [3 ]
Al-Hammadi, Noor [2 ]
Jain, Yogesh [4 ]
Gage, Brian [1 ]
机构
[1] Washington Univ, Dept Med, St Louis, MO USA
[2] Washington Univ, Div Biostat, St Louis, MO 63110 USA
[3] Columbia Univ, Med Ctr, Dept Hosp Med, New York, NY USA
[4] Jan Swasthya Sahyog, Ganiyari, Chhattisgarh, India
关键词
INTERNATIONAL NORMALIZED RATIO; ATRIAL-FIBRILLATION; ORAL ANTICOAGULANT; STROKE; THERAPY; METAANALYSIS; DABIGATRAN; INTENSITY; EFFICACY; OUTCOMES;
D O I
10.4103/ijmr.IJMR_1201_18
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background & objectives: In most of rural India, warfarin is the only oral anticoagulant available. Among patients taking warfarin, there is a strong association between poor control of the international normalized ratio (INR) and adverse events. This study was aimed to quantify INR control in a secondary healthcare system in rural Chhattisgarh, India. Methods: The INR data were retrospectively obtained from all patients taking warfarin during 2014-2016 at a secondary healthcare system in rural Chhattisgarh, India. Patients attending the clinic had their INR checked at the hospital laboratory and their warfarin dose adjusted by a physician on the same day. The time in therapeutic range (TTR) was calculated for patients who had at least two INR visits. Results: The 249 patients had 2839 INR visits. Their median age was 46 yr, and the median body mass index was 17.7 kg/m[2]. They lived a median distance of 78 km (2-3 h of travel) from the hospital. The median INR was 1.7 for a target INR of 2.0-3.0 (n=221) and 2.1 for a target of 2.5-3.5 (n=28). The median TTR was 13.0 per cent, and INR was subtherapeutic 66.0 per cent of the time. Distance from the hospital was not correlated with TTR. Interpretation & conclusions: INR values were subtherapeutic two-thirds of the time, and TTR values were poor regardless of distance from the health centre. Future studies should be done to identify interventions to improve INR control.
引用
收藏
页码:303 / 307
页数:5
相关论文
共 50 条
  • [21] Pharmaceutical Care Increases Time in Therapeutic Range of Patients With Poor Quality of Anticoagulation With Warfarin
    Marcatto, Leiliane Rodrigues
    Sacilotto, Luciana
    Tavares, Leticia Camargo
    Facin, Mirella
    Olivetti, Natalia
    Cassaro Strunz, Celia Maria
    Costa Darrieux, Francisco Carlos
    Scanavacca, Mauricio Ibrahim
    Krieger, Jose Eduardo
    Pereira, Alexandre Costa
    Junior Lima Santos, Paulo Caleb
    FRONTIERS IN PHARMACOLOGY, 2018, 9
  • [22] New Internet-Based Warfarin Anticoagulation Management Approach After Mechanical Heart Valve Replacement: Prospective, Multicenter, Randomized Controlled Trial
    Zhu, Zhihui
    Li, Chenyu
    Shen, Jinglun
    Wu, Kaisheng
    Li, Yuehuan
    Liu, Kun
    Zhang, Fan
    Zhang, Zhenhua
    Li, Yan
    Han, Jie
    Qin, Ying
    Yang, Yu
    Fan, Guangpu
    Zhang, Huajun
    Ding, Zheng
    Xu, Dong
    Chen, Yu
    Zheng, Yingli
    Zheng, Zhe
    Meng, Xu
    Zhang, Haibo
    JOURNAL OF MEDICAL INTERNET RESEARCH, 2021, 23 (08)
  • [23] Individual and monitoring centre influences upon anticoagulation control of AF patients on warfarin: A longitudinal multi-centre UK-based study
    Abohelaika, Salah
    Wynne, Hilary
    Avery, Peter
    Robinson, Brian
    Jones, Lisa
    Tait, Campbell
    Dickinson, Bradley
    Salisbury, Julie
    Nightingale, Joanna
    Green, Louise
    Kamali, Farhad
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2018, 101 (04) : 486 - 495
  • [24] Standard-Intensity Versus Low-Intensity Anticoagulation with Warfarin in Asian Patients with Atrial Fibrillation: A Multi-Center, Randomized Controlled Trial
    Cho, Jeong Gwan
    Lee, Ki Hong
    Kim, Yoo Ri
    Kim, Sunah
    Gwak, Jisoo
    Cho, Eunbit
    Sin, Yourim
    Shin, Seung Yong
    Park, Hyung Wook
    Ko, Jum Suk
    Kim, Nam Ho
    Park, Yae Min
    Lee, Jung Myung
    Yoon, Nam Sik
    Kim, Sung Soo
    Kim, Jun Hyung
    Kim, Dong Min
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2023, 29
  • [25] Uninterrupted Warfarin Anticoagulation for Atrial Fibrillation Ablation: Too Good to Be True?
    Winkle, Roger A.
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2014, 37 (06): : 661 - 664
  • [26] Assessment of anticoagulation management in outpatients attending a warfarin clinic in Windhoek, Namibia
    Jonkman, Lauren J.
    Gwanyanya, Marvelous P.
    Kakololo, Monika N.
    Verbeeck, Roger K.
    Singu, Bonifasius S.
    DRUGS & THERAPY PERSPECTIVES, 2019, 35 (07) : 341 - 346
  • [27] Quality of anticoagulation control and hemorrhage risk among African American and European American warfarin users
    Limdi, Nita A.
    Brown, Todd M.
    Shendre, Aditi
    Liu, Nianjun
    Hill, Charles E.
    Beasley, Timothy M.
    PHARMACOGENETICS AND GENOMICS, 2017, 27 (10) : 347 - 355
  • [28] Who Will Achieve Stable Anticoagulation Therapy With Warfarin?
    An, Yoshimori
    Akao, Masaharu
    CIRCULATION JOURNAL, 2018, 82 (01) : 17 - 18
  • [29] Intensity and Quality of Warfarin Anticoagulation in Chinese Patients Setting the Record Straight
    Eikelboom, John W.
    Hart, Robert G.
    STROKE, 2015, 46 (01) : 5 - 6
  • [30] Peri-procedural interrupted oral anticoagulation for atrial fibrillation ablation: comparison of aspirin, warfarin, dabigatran, and rivaroxaban
    Winkle, Roger A.
    Mead, R. Hardwin
    Engel, Gregory
    Kong, Melissa H.
    Patrawala, Rob A.
    EUROPACE, 2014, 16 (10): : 1443 - 1449